yttrium Y 90-clivatuzumab tetraxetan

{
  "id": "MLC-T-ONC-009445",
  "term": "yttrium Y 90-clivatuzumab tetraxetan",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of advanced pancreatic cancer. Yttrium Y 90-clivatuzumab tetraxetan contains a monoclonal antibody that binds to a protein called MUC-1, which is found on some pancreatic cancer cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. Yttrium Y 90-clivatuzumab tetraxetan is a type of radioimmunoconjugate. Also called yttrium Y 90-DOTA monoclonal antibody HuPAM4.",
    "A radioimmunoconjugate comprised of the humanized monoclonal antibody HuPAM4, directed against the pancreatic cancer antigen MUC1, that is conjugated to the chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA) and radiolabeled with the beta-emitting radioisotope Yttrium Y90. Yttrium Y 90 clivatuzumab tetraxetan binds to tumor cells expressing MUC1 antigen, selectively delivering a cytotoxic dose of beta radiation."
  ],
  "abbreviation": "Y90 DOTA MOAB HuPAM4",
  "synonyms": [
    "yttrium Y 90-DOTA monoclonal antibody HuPAM4",
    "yttrium Y 90 DOTA monoclonal antibody HuPAM4",
    "90Y-hPAM4",
    "hPAM4-DOTA"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/yttrium-y-90-clivatuzumab-tetraxetan/"
}